Bruce C. Cozadd - Nov 1, 2021 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role: Chairman & CEO, Director
Signature: By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd
Stock symbol: JAZZ
Transactions as of: Nov 1, 2021
Transactions value $: -$429,140
Form type: 4
Date filed: 11/3/2021, 04:43 PM
Previous filing: Oct 6, 2021
Next filing: Dec 3, 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JAZZ	Ordinary Shares	Options Exercise	$454K	+9.7K	+3.11%	$46.83	322K	Nov 1, 2021	Direct	F1
transaction	JAZZ	Ordinary Shares	Sale	-$253K	-1.89K	-0.59%	$133.70	320K	Nov 1, 2021	Direct	F2, F3
transaction	JAZZ	Ordinary Shares	Sale	-$261K	-1.93K	-0.6%	$134.78	318K	Nov 1, 2021	Direct	F2, F4
transaction	JAZZ	Ordinary Shares	Sale	-$370K	-2.73K	-0.86%	$135.45	316K	Nov 1, 2021	Direct	F2, F5

Showing 1 to 4 of 4 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JAZZ	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-9.7K	-10.01%	$0.00	87.2K	Nov 1, 2021	Ordinary Shares	9.7K	$46.83	Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.
F3	Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $133.08 to $134.03. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4	Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $134.163 to $135.134. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5	Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.181 to $135.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F6	This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.